Financial planning tied to 56% lower death rate among high-risk cancer patients, separate program aids 3,500 more

Divide that grant pool by the caseload and each patient's plan carries roughly $200 of funding ^[1], which against the three-meeting protocol is about $67 of paid-for time per meeting ^[2]. No advisor bills at that rate, so what the Foundation for Financial Planning has built is charity infrastructure with a clinical thesis attached, not a service line.

The capacity arithmetic is harder. Spread across 2018 to 2025 the programme averages something near 440 patients a year ^[3], and Taylor Jessee of Impact Financial, who takes two or three pro bono cancer cases a year through the Virginia nonprofit Cancerlinc ^[8], is a reasonable unit of supply: at that caseload the whole national effort is under 200 advisors' worth of volunteer hours ^[4], six to nine unbilled meetings each ^[6]. With diagnoses trending up among people under 50, and Memorial Sloan Kettering listing colorectal, breast, prostate, uterine, stomach and pancreatic among the cancers showing up younger ^[9], demand is not the scarce input here.

Which points the billable version somewhere else: at the household already paying a retainer, with the work done before anyone is sick rather than inside the few weeks Dr. Carolyn McClanahan describes between diagnosis and the start of treatment ^[1]. Matthew Wolniewicz, president of Income America, makes the failure mode concrete. He was treated for non-Hodgkin's lymphoma in 2018, learned last year (after what first looked like a stroke) that it had returned, and is now in remission approaching six months past a March stem-cell transplant ^[10]. He and his wife see their advisor twice a year, and still could not reach his accounts when he was hospitalised, because she held no passwords and he could not remember his own ^[12]. The breakdown, in the end, came down to a login screen neither of them could get past.

The load-bearing figure is the 56% ^[5], and it is also the softest. The reporting gives no study name, cohort size, or design ^[15], and the confound sits in plain view: a patient with the energy, family support and paperwork to sit through three planning sessions in the weeks before treatment is not a random draw from the population that dies during it. This is probably partly selection, or rather, the more interesting version is that some of it is selection and the residual still matters, because the 107-patient blood-cancer pilot reports quality-of-life gains that need no survival claim to stand up ^[4], and the National Cancer Institute's use of financial toxicity as a term rests on the money problem having medical consequences at all ^[2].

The smaller number is the more usable one. Jon Dauphine, who runs the Foundation, was over $1,000 out of pocket in his first week of treatment this year with insurance he calls good ^[13], and his own point is that most Americans do not hold $1,000 for emergencies ^[14], so week one clears the buffer entirely ^[5]. What planning sells into that gap is benefits sequencing, credential access and cash timing, none of which look like portfolio work and all of which are chargeable.

How the mortality effect reads depends on where it comes from. If it is mostly selection, the offering prices as comfort rather than as medicine, and the ceiling is whatever a household pays for contingency documents. If intake genuinely takes longer than the window, the pro bono channel is structurally late, and the only version that arrives on time is the one written while the client is well.